-
Je něco špatně v tomto záznamu ?
EULAR definition of difficult-to-treat rheumatoid arthritis
G. Nagy, NMT. Roodenrijs, PM. Welsing, M. Kedves, A. Hamar, MC. van der Goes, A. Kent, M. Bakkers, E. Blaas, L. Senolt, Z. Szekanecz, E. Choy, M. Dougados, JW. Jacobs, R. Geenen, HW. Bijlsma, A. Zink, D. Aletaha, L. Schoneveld, P. van Riel, L....
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem
NLK
ProQuest Central
od 1939-01-01 do Před 6 měsíci
Health & Medicine (ProQuest)
od 1939-01-01 do Před 6 měsíci
Family Health Database (ProQuest)
od 1939-01-01 do Před 6 měsíci
- MeSH
- antirevmatika terapeutické užití MeSH
- biologické přípravky terapeutické užití MeSH
- glukokortikoidy terapeutické užití MeSH
- kombinovaná farmakoterapie MeSH
- léková rezistence MeSH
- lidé MeSH
- poradní výbory MeSH
- progrese nemoci MeSH
- revmatoidní artritida diagnostické zobrazování farmakoterapie patofyziologie MeSH
- revmatologie MeSH
- směrnice pro lékařskou praxi jako téma MeSH
- terapie neúspěšná MeSH
- terminologie jako téma MeSH
- účast zainteresovaných stran MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Geografické názvy
- Evropa MeSH
BACKGROUND: Despite treatment according to the current management recommendations, a significant proportion of patients with rheumatoid arthritis (RA) remain symptomatic. These patients can be considered to have 'difficult-to-treat RA'. However, uniform terminology and an appropriate definition are lacking. OBJECTIVE: The Task Force in charge of the "Development of EULAR recommendations for the comprehensive management of difficult-to-treat rheumatoid arthritis" aims to create recommendations for this underserved patient group. Herein, we present the definition of difficult-to-treat RA, as the first step. METHODS: The Steering Committee drafted a definition with suggested terminology based on an international survey among rheumatologists. This was discussed and amended by the Task Force, including rheumatologists, nurses, health professionals and patients, at a face-to-face meeting until sufficient agreement was reached (assessed through voting). RESULTS: The following three criteria were agreed by all Task Force members as mandatory elements of the definition of difficult-to-treat RA: (1) Treatment according to European League Against Rheumatism (EULAR) recommendation and failure of ≥2 biological disease-modifying antirheumatic drugs (DMARDs)/targeted synthetic DMARDs (with different mechanisms of action) after failing conventional synthetic DMARD therapy (unless contraindicated); (2) presence of at least one of the following: at least moderate disease activity; signs and/or symptoms suggestive of active disease; inability to taper glucocorticoid treatment; rapid radiographic progression; RA symptoms that are causing a reduction in quality of life; and (3) the management of signs and/or symptoms is perceived as problematic by the rheumatologist and/or the patient. CONCLUSIONS: The proposed EULAR definition for difficult-to-treat RA can be used in clinical practice, clinical trials and can form a basis for future research.
Centre for Rheumatic Diseases King's College London London UK
Department of Genetics Cell and Immunobiology Semmelweis University Budapest Hungary
Department of Psychology Utrecht University Utrecht the Netherlands
Department of Rheumatic Diseases Radboud University Nijmegen Medical Centre Nijmegen the Netherlands
Department of Rheumatology Bács Kiskun County Hospital Kecskemét Hungary
Department of Rheumatology Bravis Hospital Roosendaal the Netherlands
Department of Rheumatology Faculty of Medicine University of Debrecen Debrecen Hungary
Department of Rheumatology Leiden University Medical Center Leiden the Netherlands
Department of Rheumatology Meander Medical Center Amersfoort the Netherlands
EULAR Standing Committee of People with Arthritis Rheumatism in Europe Zurich Switzerland
Institute of Infection Immunity and Inflammation University of Glasgow Glasgow UK
Leeds Institute of Rheumatic and Musculoskeletal Medicine University of Leeds Leeds UK
Salisbury Foundation Trust NHS Hospital Wiltshire UK
School of Health and Society Centre for Health Sciences Research University of Salford Salford UK
School of Medicine Catholic University of the Sacred Heart Rome Italy
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21011638
- 003
- CZ-PrNML
- 005
- 20210507101603.0
- 007
- ta
- 008
- 210420s2021 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1136/annrheumdis-2020-217344 $2 doi
- 035 __
- $a (PubMed)33004335
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Nagy, György $u Department of Rheumatology, 3rd Department of Internal Medicine, Semmelweis University, Budapest, Hungary nagy.gyorgy2@med.semmelweis-univ.hu $u Department of Genetics, Cell and Immunobiology, Semmelweis University, Budapest, Hungary
- 245 10
- $a EULAR definition of difficult-to-treat rheumatoid arthritis / $c G. Nagy, NMT. Roodenrijs, PM. Welsing, M. Kedves, A. Hamar, MC. van der Goes, A. Kent, M. Bakkers, E. Blaas, L. Senolt, Z. Szekanecz, E. Choy, M. Dougados, JW. Jacobs, R. Geenen, HW. Bijlsma, A. Zink, D. Aletaha, L. Schoneveld, P. van Riel, L. Gutermann, Y. Prior, E. Nikiphorou, G. Ferraccioli, G. Schett, KL. Hyrich, U. Mueller-Ladner, MH. Buch, IB. McInnes, D. van der Heijde, JM. van Laar
- 520 9_
- $a BACKGROUND: Despite treatment according to the current management recommendations, a significant proportion of patients with rheumatoid arthritis (RA) remain symptomatic. These patients can be considered to have 'difficult-to-treat RA'. However, uniform terminology and an appropriate definition are lacking. OBJECTIVE: The Task Force in charge of the "Development of EULAR recommendations for the comprehensive management of difficult-to-treat rheumatoid arthritis" aims to create recommendations for this underserved patient group. Herein, we present the definition of difficult-to-treat RA, as the first step. METHODS: The Steering Committee drafted a definition with suggested terminology based on an international survey among rheumatologists. This was discussed and amended by the Task Force, including rheumatologists, nurses, health professionals and patients, at a face-to-face meeting until sufficient agreement was reached (assessed through voting). RESULTS: The following three criteria were agreed by all Task Force members as mandatory elements of the definition of difficult-to-treat RA: (1) Treatment according to European League Against Rheumatism (EULAR) recommendation and failure of ≥2 biological disease-modifying antirheumatic drugs (DMARDs)/targeted synthetic DMARDs (with different mechanisms of action) after failing conventional synthetic DMARD therapy (unless contraindicated); (2) presence of at least one of the following: at least moderate disease activity; signs and/or symptoms suggestive of active disease; inability to taper glucocorticoid treatment; rapid radiographic progression; RA symptoms that are causing a reduction in quality of life; and (3) the management of signs and/or symptoms is perceived as problematic by the rheumatologist and/or the patient. CONCLUSIONS: The proposed EULAR definition for difficult-to-treat RA can be used in clinical practice, clinical trials and can form a basis for future research.
- 650 _2
- $a poradní výbory $7 D026683
- 650 _2
- $a antirevmatika $x terapeutické užití $7 D018501
- 650 _2
- $a revmatoidní artritida $x diagnostické zobrazování $x farmakoterapie $x patofyziologie $7 D001172
- 650 _2
- $a biologické přípravky $x terapeutické užití $7 D001688
- 650 _2
- $a progrese nemoci $7 D018450
- 650 _2
- $a léková rezistence $7 D004351
- 650 _2
- $a kombinovaná farmakoterapie $7 D004359
- 650 _2
- $a glukokortikoidy $x terapeutické užití $7 D005938
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a směrnice pro lékařskou praxi jako téma $7 D017410
- 650 _2
- $a revmatologie $7 D012219
- 650 _2
- $a účast zainteresovaných stran $7 D000073597
- 650 _2
- $a terminologie jako téma $7 D009626
- 650 _2
- $a terapie neúspěšná $7 D017211
- 651 _2
- $a Evropa $7 D005060
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Roodenrijs, Nadia Mt $u Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands
- 700 1_
- $a Welsing, Paco Mj $u Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands
- 700 1_
- $a Kedves, Melinda $u Department of Rheumatology, Bács-Kiskun County Hospital, Kecskemét, Hungary
- 700 1_
- $a Hamar, Attila $u Department of Rheumatology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary
- 700 1_
- $a van der Goes, Marlies C $u Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands $u Department of Rheumatology, Meander Medical Center, Amersfoort, the Netherlands
- 700 1_
- $a Kent, Alison $u Salisbury Foundation Trust NHS Hospital, Wiltshire, UK
- 700 1_
- $a Bakkers, Margot $u EULAR Standing Committee of People with Arthritis/Rheumatism in Europe (PARE), Zurich, Switzerland
- 700 1_
- $a Blaas, Etienne $u Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands
- 700 1_
- $a Senolt, Ladislav $u Department of Rheumatology, 1st Faculty of Medicine, Charles University and Institute of Rheumatology, Prague, Czech Republic
- 700 1_
- $a Szekanecz, Zoltan $u Department of Rheumatology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary
- 700 1_
- $a Choy, Ernest $u CREATE Centre, Section of Rheumatology, School of Medicine, Division of Infection and Immunity, Cardiff University, Cardiff, UK
- 700 1_
- $a Dougados, Maxime $u Université de Paris Department of Rheumatology - Hôpital Cochin. Assistance Publique - Hôpitaux de Paris INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité, Paris, France
- 700 1_
- $a Jacobs, Johannes Wg $u Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands
- 700 1_
- $a Geenen, Rinie $u Department of Psychology, Utrecht University, Utrecht, the Netherlands
- 700 1_
- $a Bijlsma, Hans Wj $u Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands
- 700 1_
- $a Zink, Angela $u Epidemiology Unit, German Rheumatism Research Centre, and Rheumatology, Charité, University Medicine, Berlin, Germany
- 700 1_
- $a Aletaha, Daniel $u Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria
- 700 1_
- $a Schoneveld, Leonard $u Department of Rheumatology, Bravis Hospital, Roosendaal, the Netherlands
- 700 1_
- $a van Riel, Piet $u Department of Rheumatic Diseases, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands
- 700 1_
- $a Gutermann, Loriane $u Department of Pharmacy, Paris Descartes University, Hôpital Cochin, Assistance Publique Hôpitaux de Paris, Paris, France
- 700 1_
- $a Prior, Yeliz $u School of Health and Society, Centre for Health Sciences Research, University of Salford, Salford, UK
- 700 1_
- $a Nikiphorou, Elena $u Centre for Rheumatic Diseases, King's College London, London, UK
- 700 1_
- $a Ferraccioli, Gianfranco $u School of Medicine, Catholic University of the Sacred Heart, Rome, Italy
- 700 1_
- $a Schett, Georg $u Department of Internal Medicine 3, Rheumatology and Immunology, Friedrich-Alexander University of Erlangen-Nuremberg and Universitatsklinikum Erlangen, Erlangen, Germany
- 700 1_
- $a Hyrich, Kimme L $u NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK $u Centre for Musculoskeletal Research, School of Biological Sciences, Faculty of Biology, Medicine & Health, University of Manchester, Manchester, UK
- 700 1_
- $a Mueller-Ladner, Ulf $u Department of Rheumatology and Clinical Immunology, Justus-Liebig University Giessen, Kerckhoff Clinic Bad Nauheim, Bad Nauheim, Germany
- 700 1_
- $a Buch, Maya H $u NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK $u Centre for Musculoskeletal Research, School of Biological Sciences, Faculty of Biology, Medicine & Health, University of Manchester, Manchester, UK $u Leeds Institute of Rheumatic & Musculoskeletal Medicine, University of Leeds, Leeds, UK
- 700 1_
- $a McInnes, Iain B $u Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK
- 700 1_
- $a van der Heijde, Désirée $u Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands
- 700 1_
- $a van Laar, Jacob M $u Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands
- 773 0_
- $w MED00000444 $t Annals of the rheumatic diseases $x 1468-2060 $g Roč. 80, č. 1 (2021), s. 31-35
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33004335 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20210420 $b ABA008
- 991 __
- $a 20210507101603 $b ABA008
- 999 __
- $a ok $b bmc $g 1650106 $s 1132017
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 80 $c 1 $d 31-35 $e 20201001 $i 1468-2060 $m Annals of the rheumatic diseases $n Ann Rheum Dis $x MED00000444
- LZP __
- $a Pubmed-20210420
